Search Results - "SEROOGY, Joseph"

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer by Gomez, Henry L, Philco, Manuel, Pimentel, Patricia, Kiyan, Miriam, Monsalvo, Maria Laura, Conlan, Maureen G, Saikali, Khalil G, Chen, Michael M, Seroogy, Joseph J, Wolff, Andrew A, Escandon, Rafael D

“…The objective of the study was to evaluate the safety, pharmacokinetics, and antitumor activity of ispinesib, a kinesin spindle protein inhibitor. Patients…”
Get full text

Identification of Orally Active, Potent, and Selective 4-Piperazinylquinazolines as Antagonists of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase Family by Pandey, Anjali, Volkots, Deborah L, Seroogy, Joseph M, Rose, Jack W, Yu, Jin-Chen, Lambing, Joseph L, Hutchaleelaha, Athiwat, Hollenbach, Stanley J, Abe, Keith, Giese, Neill A, Scarborough, Robert M

“…We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent and selective inhibitors of…”
Get full text

Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists by Mehrotra, Mukund M., Heath, Julie A., Smyth, Mark S., Pandey, Anjali, Rose, Jack W., Seroogy, Joseph M., Volkots, Deborah L., Nannizzi-Alaimo, Lisa, Park, Gary L., Lambing, Joseph L., Hollenbach, Stanley J., Scarborough, Robert M.

“…In our efforts to develop orally active GPIIb-IIIa antagonists with improved pharmaceutical properties, we have utilized a novel 2,8-diazaspiro[4.5]decane…”
Get full text

The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study by O'Connor, Owen A, Gerecitano, John, Van Deventer, Henrik, Hainsworth, John, Zullo, Kelly M, Saikali, Khalil, Seroogy, Joseph, Wolff, Andrew, Escandón, Rafael

“…This was a phase I study of SB-743921 (SB-921) in patients with relapsed/refractory lymphoma. Previous studies established that neutropenia was the only dose…”
Get full text

A novel monoclonal antibody dependent on domain 5 of the platelet-derived growth factor beta receptor inhibits ligand binding and receptor activation by Ramakrishnan, V, Escobedo, M A, Fretto, L J, Seroogy, J J, Tomlinson, J E, Wolf, D L

“…Platelet derived growth factor (PDGF) induces activation of the protein tyrosine kinase domain of the PDGF receptor, resulting in receptor dimerization and the…”
Get more information

Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: Synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes by MEHROTRA, Mukund M, HEATH, Julie A, PANDEY, Anjali, SCARBOROUGH, Robert M, ROSE, Jack W, SMYTH, Mark S, SEROOGY, Joseph, VOLKOTS, Deborah L, RUHTER, Gerd, SCHOTTEN, Theo, ALAIMO, Lisa, PARK, Gary

“…The synthesis and biological activity of analogues containing spiro piperidinylpyridine and pyrrolidinylpyridine templates are described. The potent activity…”
Get full text

Mechanism of platelet-derived growth factor (PDGF) AA, AB, and BB binding to alpha and beta PDGF receptor by FRETTO, L. J, SNAPE, A. J, TOMLINSON, J. E, SEROOGY, J. J, WOLF, D. L, LAROCHELLE, W. J, GIESE, N. A

“…The biological effects of platelet-derived growth factor (PDGF) are mediated by cell surface alpha and beta PDGF receptors, which, as a result of ligand…”
Get full text

The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphoma: results of an international, multicenter phase I/II study by O'Connor, Owen A., Gerecitano, John, Van Deventer, Henrik, Hainsworth, John, Zullo, Kelly M., Saikali, Khalil, Seroogy, Joseph, Wolff, Andrew, Escandón, Rafael

“…This was a phase I study of SB-743921 (SB-921) in patients with relapsed/refractory lymphoma. Previous studies established that neutropenia was the only dose…”
Get full text